Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy SAN DIEGO , June 11, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of DRAGEN™ v4.3, the latest version of its DRAGEN™ software, part of the Illumina Connected Software portfolio, for analysis of next-generation sequencing data. "We are excited to launch DRAGEN v4.3, with significant enhancements and additions to our analysis tools, empowering researchers and geneticists to maximize the value of the genome," said Rami Mehio, head of Software & Informatics at Illumina.

Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations

CrowdStrike

Three companies are set to be added to the S&P 500, whereas another three will be removed. Companies inside the S&P 500 can be laggards, whereas companies that are removed can post strong gains -- index inclusion isn't what matters most.

Here's Why Stocks Such as CrowdStrike and KKR Jumped Today, Whereas Stocks Such as Illumina Dropped

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Report Scope

Illumina Inc. (ILMN): 2024 Company Profile, Product Pipeline Analysis, and Ongoing Clinical Trials Insights

Illumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company's decision to spin off its blood testing company – Grail.

Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?

NIKE

Genetics sequencing leader Illumina reported a strong start to 2024. Nike has been lagging the S&P 500 this year.

U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock.

EPAM Systems

Paycom Software

EPAM Systems' client demand is weaker than anticipated. Paycom's Q2 outlook disappointed investors.

Is It Time to Buy May's Worst-Performing S&P 500 Stocks?

SAN DIEGO , June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments. "We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson, head of Global Product Management at Illumina.

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

Illumina , a maker of gene sequencing machines, said on Monday it expected to spin off cancer test maker Grail.

Illumina to spin off Grail in June

"When-issued" trading expected to begin on or about June 12, 2024 Record date for distribution of GRAIL shares will be June 13, 2024 Distribution date for GRAIL shares anticipated to be June 24, 2024 SAN DIEGO , June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024, and has applied to list on Nasdaq as "GRAL.

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

Illumina, Inc. (NASDAQ:ILMN ) Bernstein Strategic Decisions Conference May 29, 2024 9:00 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Eve Burstein - Bernstein Research Eve Burstein Thanks so much for joining us. My name is Eve Burstein.

Illumina, Inc. (ILMN) Bernstein Strategic Decisions Conference (Transcript)

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD SAN DIEGO , May 29, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4 in Chicago. Highlights include data from several studies in partnership with Labcorp, a global leader of innovative and comprehensive laboratory services; research with Sarah Cannon Research Institute (SCRI) demonstrating further evidence to support the use of comprehensive genomic profiling (CGP) over single-gene testing (SGT); and the latest data supporting the development of Illumina's molecular residual disease (MRD) assay, which is currently underway in collaboration with major pharma companies.

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

BeiGene

Baidu

Sirius XM Holdings Inc

Toronto-Dominion Bank

VinFast Auto Ltd

Warner Bros Discovery Inc

The speed of growth of a given stock is much higher the smaller it is. Stock size is classified by market capitalization – current share price x number of shares outstanding – with large cap shares being above $10 billion.

7 Large-Cap Stocks That Can Jump 50% By 2025

SAN DIEGO , May 28, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social Responsibility (CSR) Report. The report highlights the company's ongoing commitments and progress made in 2023 toward advancing human health by serving as a champion for patients, communities, employees, and the planet.

Illumina releases 2023 Corporate Social Responsibility Report

SAN CARLOS, Calif.--(BUSINESS WIRE)-- #age--Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced they have joined Illumina Ventures Labs to integrate the company's drug discovery engine with Illumina sequencing. This partnership provides monetary and scientific support, enabling Integrated Biosciences to discover and design new classes of small molecule therapeutics.

Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome

Ms. Richo brings more than 30 years of global legal, compliance, and regulatory experience  to Illumina's Board SAN DIEGO , May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024, annual meeting. Ms. Richo currently serves as Corporate Senior Vice President, Strategic Advisor to the General Counsel and CEO at Cargill, Inc. a global food production and agricultural company.

Anna Richo joins Illumina's Board of Directors

SAN DIEGO , May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40th Annual Strategic Decisions Conference on May 29, 2024 Fireside chat at 6:00am Pacific Time (9:00am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at  investor.illumina.com . A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.

Illumina To Webcast Upcoming Investor Conference

Illumina, Inc. (NASDAQ:ILMN ) RBC Capital Markets Global Healthcare Call May 14, 2024 8:30 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Investor Relations Conference Call Participants Conor McNamara - RBC Capital Markets Conor McNamara Good morning, everyone. Welcome to RBC Capital Markets 2024 Global Healthcare Conference.

Illumina, Inc. (ILMN) RBC Capital Markets Global Healthcare (Transcript)

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC announced today that it will host a virtual Capital Markets Day.

GRAIL to Host Capital Markets Day

Global X Genomics & Biotechnology ETF

Twist Bioscience Corp

Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

GRAIL to host Capital Markets Day on May 13, 2024  SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required.

Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL

Illumina reported a non-GAAP diluted EPS of $0.09 for Q1 2024, surpassing analysts' forecasts. Despite beating estimates, the company observed a 1% decline in consolidated revenue year-over-year.

Illumina's Q1 Earnings Beat Estimates

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens

Illumina, Inc. (NASDAQ:ILMN ) Q1 2024 Earnings Call Transcript May 2, 2024 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Joydeep Goswami - Advisor Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen David Westenberg - Piper Sandler Subha Nambi - Guggenheim Securities Sung Ji Nam - Scotiabank Tejas Savant - Morgan Stanley Mason Carrico - Stephens Rachel Vatnsdal - JPMorgan Patrick Donnelly - Citi Eve Burstein - Bernstein Research Conor McNamara - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.

Illumina, Inc. (ILMN) Q1 2024 Earnings Call Transcript

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say

Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.

News for Illumina Stock (ILMN)